See every side of every news story
Get Started
SubscribeLogin
Pope Francis
Vatican
Olaf Scholz
Volodymyr Zelenskyy
Ukraine War
Donald Trump
German Politics
Israel-Hamas Conflict
Tennis
Basketball
Baseball
Elon Musk
Published • loading... • Updated

Cabaletta Bio Reveals Promising Clinical Data for Autoimmune Therapy

Summary by MyChesCo
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) shared new and updated results from its RESET clinical development program at major scientific conferences, presenting data on the first 10 patients treated with resecabtagene autoleucel (rese-cel) for autoimmune diseases. These findings indicate strong efficacy, a favorable safety profile, and the potential for drug-free remission in patients with severe, refractory conditions. Promising Cli…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

3 Articles

All
Left
Center
Right
themarketsdaily.comthemarketsdaily.com

Cabaletta Bio (NASDAQ:CABA) Given “Buy” Rating at HC Wainwright

Cabaletta Bio (NASDAQ:CABA – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They presently have a $25.00 target price on the stock. A number of other equities research analysts have also recently issued reports on the company. Evercore ISI cut […]

Read Full Article
MyChesCoMyChesCo

Cabaletta Bio Reveals Promising Clinical Data for Autoimmune Therapy

PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) shared new and updated results from its RESET clinical development program at major scientific conferences, presenting data on the first 10 patients treated with resecabtagene autoleucel (rese-cel) for autoimmune diseases. These findings indicate strong efficacy, a favorable safety profile, and the potential for drug-free remission in patients with severe, refractory conditions. Promising Cli…

Read Full Article
Labiotech.euLabiotech.eu

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

T cell engagers represent a novel approach to tuning the immune system to target and kill tumor cells, expanding treatment options for cancer. The post T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strict…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Labiotech.eu broke the news in on Tuesday, February 18, 2025.
Sources are mostly out of (0)

Similar News Topics

Cancer

Cancer

Stock Markets

Stock Markets

News
For You
Search
BlindspotLocal